Merck Serono

Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Darmstadt, Germany, and a brand and division of Merck focused on biopharmaceuticals.

Merck KGaA and Serono operated as distinct entities until at least January 2007.

In 2012, Merck Serono moved its headquarters from Geneva, Switzerland to Darmstadt.

Drugs they market include Erbitux, UFT, Rebif, Mavenclad, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive, Luveris, Saizen, Serostim, Glucophage, Concor and Euthyrox.

[2][3] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.

The former headquarters of Merck Serono in Geneva (which now hosts the Campus Biotech ).